CA3237155A1 - Therapeutic compounds for hiv virus infection - Google Patents
Therapeutic compounds for hiv virus infection Download PDFInfo
- Publication number
- CA3237155A1 CA3237155A1 CA3237155A CA3237155A CA3237155A1 CA 3237155 A1 CA3237155 A1 CA 3237155A1 CA 3237155 A CA3237155 A CA 3237155A CA 3237155 A CA3237155 A CA 3237155A CA 3237155 A1 CA3237155 A1 CA 3237155A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitors
- hiv
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285753P | 2021-12-03 | 2021-12-03 | |
| US63/285,753 | 2021-12-03 | ||
| PCT/US2022/080823 WO2023102529A1 (en) | 2021-12-03 | 2022-12-02 | Therapeutic compounds for hiv virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3237155A1 true CA3237155A1 (en) | 2023-06-08 |
Family
ID=84943709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3237155A Pending CA3237155A1 (en) | 2021-12-03 | 2022-12-02 | Therapeutic compounds for hiv virus infection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12084467B2 (https=) |
| EP (1) | EP4440700A1 (https=) |
| JP (2) | JP7765637B2 (https=) |
| KR (1) | KR20240117588A (https=) |
| CN (1) | CN118355020A (https=) |
| AU (1) | AU2022399845B2 (https=) |
| CA (1) | CA3237155A1 (https=) |
| TW (1) | TW202342448A (https=) |
| WO (1) | WO2023102529A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2025240387A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367382A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367385A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367381A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
Family Cites Families (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| US20020119443A1 (en) | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
| ATE380175T1 (de) | 2001-06-27 | 2007-12-15 | Smithkline Beecham Corp | Pyrrolidine als dipeptidyl peptidase inhibitoren |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| US7186747B2 (en) | 2004-02-27 | 2007-03-06 | Schering Corporation | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| NZ568595A (en) | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
| EP2010493B1 (en) | 2006-04-12 | 2016-01-27 | Merck Sharp & Dohme Corp. | Pyridyl amide t-type calcium channel antagonists |
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| EP2139883A4 (en) | 2007-03-23 | 2011-06-22 | Univ Massachusetts | HIV-1 protease inhibitor |
| WO2009005677A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CA2693044C (en) | 2007-07-12 | 2017-03-14 | Tibotec Pharmaceuticals | Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| JP2011500808A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドｔ型カルシウムチャネルアンタゴニスト |
| AU2008317353B2 (en) | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| HUE025528T2 (en) | 2008-04-23 | 2016-05-30 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| CN102414217A (zh) | 2009-02-25 | 2012-04-11 | 彼格泰格私人有限公司 | 用于检测基孔肯雅病毒的探针和引物 |
| US8673307B1 (en) | 2009-03-09 | 2014-03-18 | The Rockefeller University | HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| RU2016108987A (ru) | 2009-08-18 | 2018-11-26 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
| JP5694345B2 (ja) | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| US20130053381A1 (en) | 2010-05-20 | 2013-02-28 | Novartis Ag | 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| EP3195868A3 (en) | 2010-10-01 | 2017-08-02 | VentiRx Pharmaceuticals, Inc. | Therapeutic use of a tlr agonist and combination therapy |
| CN103237549A (zh) | 2010-10-01 | 2013-08-07 | 帆德制药股份有限公司 | 过敏性疾病的治疗方法 |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| EP3208263A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| SI2688403T1 (sl) | 2011-03-23 | 2017-08-31 | Trevena, Inc. | Ligandi opioidnih receptorjev in metode uporabe in izdelave istega |
| PT3590928T (pt) | 2011-04-08 | 2021-08-19 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para o tratamento de infeções virais |
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| CN103797029B (zh) | 2011-05-17 | 2016-08-17 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
| AU2012258220B2 (en) | 2011-05-18 | 2017-01-19 | Janssen Sciences Ireland Uc | Quinazoline derivatives for the treatment of viral infections and further diseases |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9493549B2 (en) | 2011-07-25 | 2016-11-15 | The Rockefeller University | Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| EP2788376B1 (en) | 2011-12-08 | 2018-10-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| RU2014140177A (ru) | 2012-03-05 | 2016-04-27 | Сипла Лимитед | Фармацевтические антиретровирусные композиции |
| US20150044137A1 (en) | 2012-03-23 | 2015-02-12 | The United States of America, as represented by the Secretary, Dep. of Health Care Human Services | Neutralizing antibodies to hiv-1 and their use |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| MX369417B (es) | 2012-08-10 | 2019-11-07 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| CN118955699A (zh) | 2012-10-18 | 2024-11-15 | 洛克菲勒大学 | 广泛中和性抗hiv抗体 |
| EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
| WO2014089152A1 (en) | 2012-12-04 | 2014-06-12 | University Of Maryland, Baltimore | Hiv-1 env-binding antibodies, fusion proteins, and methods of use |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PE20151063A1 (es) | 2012-12-27 | 2015-08-03 | Japan Tobacco Inc | DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| WO2014110323A1 (en) | 2013-01-11 | 2014-07-17 | Johnson Controls Technology Company | Vehicle interior component having a wireless charging indicator |
| SG11201506639XA (en) | 2013-02-21 | 2015-09-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| US20160244510A1 (en) | 2013-09-27 | 2016-08-25 | Duke University | Human monoclonal antibodies |
| AU2014340110B2 (en) | 2013-10-24 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2015117008A2 (en) | 2014-01-31 | 2015-08-06 | The Rockefeller University | Broadly neutralizing anti-hiv antibodies and epitope therefor |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2016014484A1 (en) | 2014-07-21 | 2016-01-28 | The Rockefeller University | Combination of broadly neutralizing hiv antibodies and viral inducers |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US11071783B2 (en) | 2015-03-19 | 2021-07-27 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
| ES2789348T3 (es) | 2015-03-20 | 2020-10-26 | Us Health | Anticuerpos neutralizantes para GP120 y sus usos |
| US10221129B2 (en) | 2015-04-23 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2016172425A1 (en) | 2015-04-23 | 2016-10-27 | Viiv Healthcare (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| US10071885B2 (en) | 2015-08-26 | 2018-09-11 | Gerard O'Brien | Vacuum lift attachment |
| CA2997955A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| WO2017096276A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| MA43389A (fr) | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| EP3383431A4 (en) | 2015-12-02 | 2019-08-28 | Agenus Inc. | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF |
| WO2017096221A1 (en) | 2015-12-02 | 2017-06-08 | The Rockefeller University | Bispecific anti-hiv broadly neutralizing antibodies |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| AU2016364891A1 (en) | 2015-12-03 | 2018-06-07 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| CN107022027B (zh) | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN107033241B (zh) | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| AR110922A1 (es) | 2017-02-06 | 2019-05-15 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| AR112257A1 (es) | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| WO2019087016A1 (en) | 2017-10-30 | 2019-05-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in hiv therapy |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| DK4257600T3 (da) | 2018-07-03 | 2025-05-26 | Gilead Sciences Inc | Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem |
| KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| CA3157275C (en) | 2019-11-26 | 2026-02-10 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| CR20240223A (es) * | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
-
2022
- 2022-12-02 US US18/061,127 patent/US12084467B2/en active Active
- 2022-12-02 AU AU2022399845A patent/AU2022399845B2/en active Active
- 2022-12-02 WO PCT/US2022/080823 patent/WO2023102529A1/en not_active Ceased
- 2022-12-02 KR KR1020247021980A patent/KR20240117588A/ko active Pending
- 2022-12-02 CN CN202280078481.0A patent/CN118355020A/zh active Pending
- 2022-12-02 JP JP2024531108A patent/JP7765637B2/ja active Active
- 2022-12-02 TW TW111146362A patent/TW202342448A/zh unknown
- 2022-12-02 CA CA3237155A patent/CA3237155A1/en active Pending
- 2022-12-02 EP EP22843585.5A patent/EP4440700A1/en active Pending
-
2025
- 2025-10-24 JP JP2025179629A patent/JP2026012232A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342448A (zh) | 2023-11-01 |
| JP2024542541A (ja) | 2024-11-15 |
| AU2022399845B2 (en) | 2026-03-26 |
| CN118355020A (zh) | 2024-07-16 |
| WO2023102529A1 (en) | 2023-06-08 |
| US20230203071A1 (en) | 2023-06-29 |
| JP7765637B2 (ja) | 2025-11-06 |
| US12084467B2 (en) | 2024-09-10 |
| JP2026012232A (ja) | 2026-01-23 |
| KR20240117588A (ko) | 2024-08-01 |
| EP4440700A1 (en) | 2024-10-09 |
| AU2022399845A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7738191B2 (ja) | Ｈｉｖウイルス感染症のための治療化合物 | |
| AU2022403012B2 (en) | Therapeutic compounds for hiv virus infection | |
| AU2022399845B2 (en) | Therapeutic compounds for hiv virus infection | |
| TWI914575B (zh) | 用於ｈｉｖ病毒感染之治療性化合物 | |
| HK40116779A (en) | Therapeutic compounds for hiv virus infection | |
| HK40116652A (en) | Therapeutic compounds for hiv virus infection | |
| HK40116652B (en) | Therapeutic compounds for hiv virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241202 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251007 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251007 |